Edward B. Garon

APLA Health — United States

Medicine · Health Sciences

76h-index54.6kcitations729works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(399), Cancer Immunotherapy and Biomarkers(282), Cancer Genomics and Diagnostics(126), Lung Cancer Diagnosis and Treatment(119), Lung Cancer Research Studies(112)

Publications721 total

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma
Cancer Research·2025Open Access
Supplementary Tables S1-S4 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS<sup>+</sup> CD4<sup>+</sup> T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
2025Open Access
Supplementary Figures S1-S8 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS<sup>+</sup> CD4<sup>+</sup> T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
2025Open Access
Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers
ONCOLOGY·2025
Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer
CHEST Journal·2025Open Access
535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
Regular and Young Investigator Award Abstracts·2025Open Access
Immune Checkpoint Inhibitor Myocarditis Masquerading as Brugada Syndrome
JACC Case Reports·2025· 1 citedOpen Access
P2.02.16 Identification of Deruxtecan-Induced Methylome Signature in NSCLC Cell Lines
Journal of Thoracic Oncology·2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
Journal of Thoracic Oncology·2025
P2.08.22 In Field Progression Rates Following Concurrent Chemoradiotherapy for Stage III Non Small Cell Lung Cancer
Journal of Thoracic Oncology·2025
Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework
The Oncologist·2025· 1 citedOpen Access
3208P 10-year outcomes from clinical trials of pembrolizumab (pembro) monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC)
Annals of Oncology·2025
Identification of Targetable <i>EGFR</i> Mutations in Ovarian Cancer
JCO Precision Oncology·2025
Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer
Lung Cancer·2025
Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy
JCO Oncology Practice·2025· 1 citedOpen Access
Adequacy of immune checkpoint inhibitor-associated thyroid function monitoring following therapy.
Journal of Clinical Oncology·2025
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS <sup>G12C</sup> mutant non-small-cell lung cancer.
Journal of Clinical Oncology·2025
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
Journal of Clinical Oncology·2025· 1 cited
Identification of targetable <i>EGFR</i> mutations in ovarian cancer.
Journal of Clinical Oncology·2025
SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with <i>HER2</i> -activating mutations.
Journal of Clinical Oncology·2025· 1 cited
page 1 of 37Next →

Frequent Co-authors

Enriqueta Felip(11), Matthew D. Hellmann(8), Rina Hui(8), Jonathan W. Goldman(7), Naiyer A. Rizvi(6), Roy S. Herbst(6), Myung‐Ju Ahn(6), Gregory M. Lubiniecki(6), Shirish M. Gadgeel(6), Maximilian J. Hochmair(6), Helge Bischoff(6), Silvia Novello(6), Marina Chiara Garassino(6), Matthew A. Gubens(6), Leora Horn(6), Martin Reck(6), Leena Gandhi(5), Delvys Rodríguez‐Abreu(5), Emilio Esteban(5), Manuel Dómine(5)